Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors

XAGE-1 is a cancer/testis (CT) antigen and has been shown to be immunogenic in lung cancer patients. Among 4 alternative splicing variants, XAGE-1a, b, c and d, XAGE-1b mRNA was dominantly expressed in cancer. In this study, we generated a XAGE-1b mAb, USO9-13. The B cell epitope recognized by the U...

Full description

Saved in:
Bibliographic Details
Published inCancer immunity Vol. 7; p. 5
Main Authors Sato, Shuichiro, Noguchi, Yuji, Ohara, Nobuya, Uenaka, Akiko, Shimono, Michihide, Nakagawa, Kazuhiko, Koizumi, Fumihito, Ishida, Toshiaki, Yoshino, Tadashi, Shiratori, Yasushi, Nakayama, Eiichi
Format Journal Article
LanguageEnglish
Published United States Academy of Cancer Immunology 05.03.2007
Subjects
Online AccessGet full text

Cover

Loading…
Abstract XAGE-1 is a cancer/testis (CT) antigen and has been shown to be immunogenic in lung cancer patients. Among 4 alternative splicing variants, XAGE-1a, b, c and d, XAGE-1b mRNA was dominantly expressed in cancer. In this study, we generated a XAGE-1b mAb, USO9-13. The B cell epitope recognized by the USO9-13 mAb was in the C-terminal region of the XAGE-1b protein and is also recognized by sera from patients with lung adenocarcinoma. Using USO9-13 and an anti-Flag mAb, we examined the translation products of the 4 transcripts. The XAGE-1a and b transcripts translated to the XAGE-1b protein. The XAGE-1c transcript possibly translated to 9- and 17-aa polypeptides. The XAGE-1d transcript translated to a protein consisting of 69 amino acids. Immunofluorescence analysis using USO9-13 mAb showed that the XAGE-1b protein is located in the nuclei of cells. Immunohistochemically, nuclear staining was heterogeneously observed in 25/47 lung adenocarcinomas, 1/12 hepatocellular carcinomas and 1/11 gastric cancers, but not in adjacent normal tissues. These findings suggested that XAGE-1b is a promising target molecule for a cancer vaccine against lung cancer.
AbstractList XAGE-1 is a cancer/testis (CT) antigen and has been shown to be immunogenic in lung cancer patients. Among 4 alternative splicing variants, XAGE-1a, b, c and d, XAGE-1b mRNA was dominantly expressed in cancer. In this study, we generated a XAGE-1b mAb, USO9-13. The B cell epitope recognized by the USO9-13 mAb was in the C-terminal region of the XAGE-1b protein and is also recognized by sera from patients with lung adenocarcinoma. Using USO9-13 and an anti-Flag mAb, we examined the translation products of the 4 transcripts. The XAGE-1a and b transcripts translated to the XAGE-1b protein. The XAGE-1c transcript possibly translated to 9- and 17-aa polypeptides. The XAGE-1d transcript translated to a protein consisting of 69 amino acids. Immunofluorescence analysis using USO9-13 mAb showed that the XAGE-1b protein is located in the nuclei of cells. Immunohistochemically, nuclear staining was heterogeneously observed in 25/47 lung adenocarcinomas, 1/12 hepatocellular carcinomas and 1/11 gastric cancers, but not in adjacent normal tissues. These findings suggested that XAGE-1b is a promising target molecule for a cancer vaccine against lung cancer.
XAGE-1 is a cancer/testis (CT) antigen and has been shown to be immunogenic in lung cancer patients. Among 4 alternative splicing variants, XAGE-1a , b , c and d , XAGE-1b mRNA was dominantly expressed in cancer. In this study, we generated a XAGE-1b mAb, USO9-13. The B cell epitope recognized by the USO9-13 mAb was in the C-terminal region of the XAGE-1b protein and is also recognized by sera from patients with lung adenocarcinoma. Using USO9-13 and an anti-Flag mAb, we examined the translation products of the 4 transcripts. The XAGE-1a and b transcripts translated to the XAGE-1b protein. The XAGE-1c transcript possibly translated to 9- and 17-aa polypeptides. The XAGE-1d transcript translated to a protein consisting of 69 amino acids. Immunofluorescence analysis using USO9-13 mAb showed that the XAGE-1b protein is located in the nuclei of cells. Immunohistochemically, nuclear staining was heterogeneously observed in 25/47 lung adenocarcinomas, 1/12 hepatocellular carcinomas and 1/11 gastric cancers, but not in adjacent normal tissues. These findings suggested that XAGE-1b is a promising target molecule for a cancer vaccine against lung cancer.
Author Shiratori, Yasushi
Ohara, Nobuya
Sato, Shuichiro
Uenaka, Akiko
Ishida, Toshiaki
Nakayama, Eiichi
Shimono, Michihide
Noguchi, Yuji
Nakagawa, Kazuhiko
Koizumi, Fumihito
Yoshino, Tadashi
AuthorAffiliation 2 Department of Gastroenterology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan
1 Department of Immunology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan
3 Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan
AuthorAffiliation_xml – name: 2 Department of Gastroenterology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan
– name: 3 Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan
– name: 1 Department of Immunology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan
Author_xml – sequence: 1
  givenname: Shuichiro
  surname: Sato
  fullname: Sato, Shuichiro
  email: sato-s@md.okayama-u.ac.jp
  organization: Department of Immunology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Shikata-cho, Okayama, Japan. sato-s@md.okayama-u.ac.jp
– sequence: 2
  givenname: Yuji
  surname: Noguchi
  fullname: Noguchi, Yuji
– sequence: 3
  givenname: Nobuya
  surname: Ohara
  fullname: Ohara, Nobuya
– sequence: 4
  givenname: Akiko
  surname: Uenaka
  fullname: Uenaka, Akiko
– sequence: 5
  givenname: Michihide
  surname: Shimono
  fullname: Shimono, Michihide
– sequence: 6
  givenname: Kazuhiko
  surname: Nakagawa
  fullname: Nakagawa, Kazuhiko
– sequence: 7
  givenname: Fumihito
  surname: Koizumi
  fullname: Koizumi, Fumihito
– sequence: 8
  givenname: Toshiaki
  surname: Ishida
  fullname: Ishida, Toshiaki
– sequence: 9
  givenname: Tadashi
  surname: Yoshino
  fullname: Yoshino, Tadashi
– sequence: 10
  givenname: Yasushi
  surname: Shiratori
  fullname: Shiratori, Yasushi
– sequence: 11
  givenname: Eiichi
  surname: Nakayama
  fullname: Nakayama, Eiichi
BackLink https://www.ncbi.nlm.nih.gov/pubmed/17335148$$D View this record in MEDLINE/PubMed
BookMark eNpVkEFLxDAQhYMo7m71L0hO3gpNkyatB2FZ1nVhwYuCnsKkTTTSJjVpRf-9FVdxT8Mwb77Hewt07LzTR2hOWM7SilM2Q4sYX7Msp3lWnKIZEZQWhJVz9LRttBussTUM1jvsDX5cbtYpwTZ640MXr3AfdOM768ANWH9MW4wHUoWtw4OOg40YXIOHsfMhnqETA23U5_uZoIeb9f3qNt3dbbar5S7tc1YNKa9ZqSitjKC8ykE3YEipjALFTcGpEaQEJcqK1CrTlQIKxqgymz6g4E1taIKuf7j9qDrd1FOcAK3sg-0gfEoPVh5enH2Rz_5d5hUtBBMT4HIPCP5tnGLIzsZaty047ccoxVQb_24sQRf_nf4sftukX1ZMc9I
ContentType Journal Article
Copyright Copyright © 2007 by Shuichiro Sato
Copyright_xml – notice: Copyright © 2007 by Shuichiro Sato
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
5PM
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

MEDLINE
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1424-9634
EndPage 5
ExternalDocumentID 17335148
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
29B
2WC
53G
5GY
6J9
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
C1A
CGR
CUY
CVF
DIK
E3Z
ECM
EIF
EJD
FRP
GX1
HYE
NPM
OK1
RPM
W2D
XSB
7X8
5PM
ID FETCH-LOGICAL-p249t-6c48b339f73692aedaf18bfbab6f563f718ab7891cb0e9ba3affb80339a56dcf3
IEDL.DBID RPM
IngestDate Fri Sep 01 02:11:03 EDT 2023
Fri Apr 12 01:21:08 EDT 2024
Wed Jul 26 02:46:59 EDT 2023
IsPeerReviewed false
IsScholarly true
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-p249t-6c48b339f73692aedaf18bfbab6f563f718ab7891cb0e9ba3affb80339a56dcf3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Contributed by: LJ Old
PMID 17335148
PQID 70236173
PQPubID 23479
PageCount 1
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_2935747
proquest_miscellaneous_70236173
pubmed_primary_17335148
PublicationCentury 2000
PublicationDate 2007-03-05
PublicationDateYYYYMMDD 2007-03-05
PublicationDate_xml – month: 03
  year: 2007
  text: 2007-03-05
  day: 05
PublicationDecade 2000
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Cancer immunity
PublicationTitleAlternate Cancer Immun
PublicationYear 2007
Publisher Academy of Cancer Immunology
Publisher_xml – name: Academy of Cancer Immunology
References 9724777 - Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10757-62
11753648 - Oncogene. 2001 Nov 22;20(53):7699-709
15657293 - J Exp Med. 2005 Jan 17;201(2):241-8
14696120 - Int J Cancer. 2004 Feb 10;108(4):558-63
10397259 - Cancer Res. 1999 Jul 1;59(13):3157-65
7544395 - J Exp Med. 1995 Sep 1;182(3):689-98
8994863 - Curr Opin Immunol. 1996 Dec;8(6):831-6
11992404 - Int J Cancer. 2002 May 20;99(3):361-9
825374 - Eur J Immunol. 1976 Apr;6(4):292-5
1955461 - J Cell Biol. 1991 Nov;115(4):887-903
15800911 - Int J Cancer. 2005 Aug 20;116(2):200-6
16061866 - Clin Cancer Res. 2005 Aug 1;11(15):5496-503
10987281 - Cancer Res. 2000 Sep 1;60(17):4752-5
12445278 - Immunol Rev. 2002 Oct;188:22-32
9651357 - J Biol Chem. 1998 Jul 10;273(28):17618-25
3031469 - Mol Cell Biol. 1987 Jan;7(1):379-87
12479262 - Mol Cancer Ther. 2002 May;1(7):441-50
11823502 - J Immunol. 2002 Feb 15;168(4):1717-22
16271074 - Cancer Sci. 2005 Nov;96(11):801-9
11861616 - Annu Rev Immunol. 2002;20:709-60
9438857 - Curr Opin Immunol. 1997 Oct 1;9(5):681-3
15905609 - Microbiol Immunol. 2005;49(5):471-6
12547500 - Trends Immunol. 2003 Feb;24(2):58-61
9432985 - J Exp Med. 1998 Jan 19;187(2):265-70
10197611 - Cancer Res. 1999 Apr 1;59(7):1445-8
12573352 - Lancet Oncol. 2003 Feb;4(2):104-9
11774264 - Int J Cancer. 2002 Jan 10;97(2):195-204
14738373 - Cancer Immun. 2004 Jan 23;4:1
11406534 - Cancer Res. 2001 Jun 15;61(12):4671-4
References_xml
SSID ssj0023205
Score 1.9147002
Snippet XAGE-1 is a cancer/testis (CT) antigen and has been shown to be immunogenic in lung cancer patients. Among 4 alternative splicing variants, XAGE-1a, b, c and...
XAGE-1 is a cancer/testis (CT) antigen and has been shown to be immunogenic in lung cancer patients. Among 4 alternative splicing variants, XAGE-1a , b , c and...
SourceID pubmedcentral
proquest
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 5
SubjectTerms Adenocarcinoma - immunology
Adenocarcinoma - metabolism
Amino Acid Sequence
Animals
Antibodies, Monoclonal - biosynthesis
Antigens, Neoplasm - immunology
Antigens, Neoplasm - metabolism
B-Lymphocytes - immunology
Cell Nucleus - metabolism
Cells, Cultured
Female
Humans
Lung Neoplasms - immunology
Lung Neoplasms - metabolism
Male
Mice
Mice, Inbred BALB C
Molecular Sequence Data
Neoplasms - immunology
Neoplasms - metabolism
Protein Isoforms - metabolism
Spermatocytes - metabolism
Spermatogonia - metabolism
Testis - immunology
Title Identification of XAGE-1 isoforms: predominant expression of XAGE-1b in testis and tumors
URI https://www.ncbi.nlm.nih.gov/pubmed/17335148
https://search.proquest.com/docview/70236173
https://pubmed.ncbi.nlm.nih.gov/PMC2935747
Volume 7
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1NS8MwGA7bDuJF_HZ-5uC1W9u0aeptDOcQJh4czFPJmyY4cGlZO_Dnm_RDNvHkOQmBJwnv87558gShe1Amj_Bc4QjrdhukgjlAmHCUTwRQw5-hKmXPXuh0HjwvwkUHhe1bmEq0L2A50J-rgV5-VNrKfCWGrU5s-DobmxAVGho87KJuREibojdZFvHd6jsa02LIAPuLOf4WQG5FlMkhOmioIB7VUx6hjtTHaG_WXHafoPf6Ea1qqmo4U3gxenp0PLwsMss1iwecW7_PWs2C5Vcjat3qCnipcWmdNArMdYrLzSpbF6doPnl8G0-d5icEJzfpUelQETAgJFYRobHPZcqVx0ABB6pCSpQJMBwiFnsCXBkDJ1wpYK4ZwUOaCkXOUE9nWl4g7IaS89ScYir9gEjDV8I4TX2A2GfM82gf3bV4JWan2esDrmW2KZLIms0bWPvovEYvyWtDjKTFuo-iHVx_OlgP690Ws7SVl3WzlJf_HnmF9utyq5UhXqNeud7IG8MTSrit9sU3-_fDyw
link.rule.ids 230,315,733,786,790,891,53827,53829
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JTsMwEB2xSMCFfSmrD1zTJnHjONwQAspSxAFQOUUexxYVNKlIKiG-HjsLAsQFzrYlK8_OvBk_PwMcojZ5hOdKR1q3224iuYOUS0f7VCIz_BnLUnb_hvXuu5eDYDAFQXMXphTtSxy205dROx0-ldrK8Uh2Gp1Y57Z_YkJUYGhwZxpmzX71wyZJr_Ms6rvlgzQhtTJ1_ht3_CmB_BJTzpbgoZlNJSV5bk8KbMv3H0aNf57uMizWLJMcV80rMKXSVZjr1-foa_BY3c_VdcGOZJoMjs9PHY8M88zS2PyIjK2VaCWUIeqt1st-6YpkmJLCmnTkRKQJKSaj7DVfh_uz07uTnlM_suCMTeZVOEx2OVIa6ZCyyBcqEdrjqFEg0wGj2sQugSGPPImuilBQoTVy14wQAUukphswk2ap2gLiBkqIxPwgmPK7VBkqFERJ4iNGPueex1pw0AARm0VsTyZEqrJJHofWx97g1YLNCpZ4XHltxA2ILQi_AfbZwdpjf28xMJQ22fVn3_73yAOY7931r-Pri5urHVioqrpW7bgLM8XrRO0ZOlLgfrn4PgAsoOXI
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3PT9swFH5iRUK7wGA_KGzUB65pk7hxnN0QtJSNVj2A1O0S-Tm2Vm1NoiaVEH_97PyYSrUT5zxLVj4n73vPnz8DXKI2dYTnSkdat9thIrmDlEtH-1QiM_wZq1b2dMYmj8Nvi2CxddVXJdqXuOynf1b9dPmr0lbmKzlodWKD-fTapKjA0OBBnujBG9g336wftYV6U2tR360upQmplarz__HHXRnkVl4ZH8HPdka1nOR3f1NiXz7vmDW-asrv4LBhm-SqDjmGPZWewMG02U9_Dz_qc7q6adyRTJPF1e3I8ciyyCydLb6S3FqK1oIZop4a3exWKJJlSkpr1lEQkSak3KyydfEBHsejh-uJ01y24OSmAisdJoccKY10SFnkC5UI7XHUKJDpgFFtcpjAkEeeRFdFKKjQGrlrRoiAJVLTj9BJs1SdAnEDJURifhRM-UOqDCUKoiTxESOfc89jXei1YMRmMdsdCpGqbFPEofWzN5h14VMNTZzXnhtxC2QXwheg_QuwNtkvnxgoKrvs5tWfvXpkDw7mN-P4_m72_Rze1s1dK3r8DJ1yvVFfDCsp8aJaf38BVU_oSA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Identification+of+XAGE-1+isoforms%3A+predominant+expression+of+XAGE-1b+in+testis+and+tumors&rft.jtitle=Cancer+immunity&rft.au=Sato%2C+Shuichiro&rft.au=Noguchi%2C+Yuji&rft.au=Ohara%2C+Nobuya&rft.au=Uenaka%2C+Akiko&rft.date=2007-03-05&rft.eissn=1424-9634&rft.volume=7&rft.spage=5&rft_id=info%3Apmid%2F17335148&rft.externalDocID=17335148